Skip to main content
. 2024 Oct 14;15:1432538. doi: 10.3389/fpsyt.2024.1432538

Table 3.

Analysis of laboratory tests by different Pittsburgh sleep quality index scores groups.

Parameters PSQI scores groups* P
Severe and very severe
(n=141)
Moderate
(n=135)
Mild
(n=114)
Normal
(n=19)
Endocrinological biomarkers
 T3 1.40 (1.24, 1.53) 1.47 (1.31, 1.61) 1.50 (1.28, 1.63) 1.42 (1.28, 1.48) 0.156
 T4 113.47 (101.71, 125.69) 108.75 (99.07, 124.19) 113.32 (99.51, 125.33) 108.89 (100.85, 111.90) 0.289
 FT3 4.87 (4.63, 5.22) 4.95 (4.56, 5.27) 5.01 (4.63, 5.33) 4.64 (4.39, 4.95) 0.185
 FT4 12.25 (11.21, 13.22) 12.25 (10.84, 13.04) 12.23 (10.92, 13.15) 12.14 (10.39, 13.73) 0.866
 TSH 1.33 (0.96, 1.92) 1.55 (0.97, 2.10) 1.61 (1.08, 2.06) 1.43 (1.31, 2.19) 0.481
 TPOAb 0.69 (0.30, 1.35) 0.50 (0.40, 1.19) 0.60 (0.30, 1.20) 0.64 (0.40, 1.00) 0.999
 TGAb 0.10 (0.00, 0.10) 0.10 (0.00, 0.10) 0.10 (0.00, 0.20) 0.10 (0.00, 0.20) 0.055
 GH 0.36 (0.16, 0.82) 0.51 (0.23, 1.37) 0.38 (0.14, 0.89) 0.26 (0.22, 0.55) 0.345
 FSH 13.99 (4.56, 52.90) 11.22 (4.47, 59.05) 9.81 (5.01, 52.19) 13.86 (4.10, 57.71) 1.000
 LH 9.88 (3.55, 21.75) 12.76 (4.59, 23.92) 7.23 (4.37, 22.48) 17.40 (8.05, 31.52) 0.515
 PRL 347.26 (249.34, 499.08) 418.43 (273.61, 534.79) 377.87 (248.83, 519.82) 351.78 (273.89, 483.44) 0.691
Tumor biomarkers
 CA125 7.50 (5.00, 10.48) 8.50 (6.00, 11.30) 7.25 (5.58, 9.65) 6.50 (4.90, 9.32) 0.197
 CA199 6.30 (3.90, 12.16) 6.60 (4.00, 8.70) 7.55 (3.90, 12.17) 6.70 (4.20, 9.32) 0.768
 AFP 2.10 (1.60, 2.71) 2.61 (1.86, 3.08) 2.20 (1.72, 2.74) 3.11 (2.30, 3.47) 0.059
 CEA 1.40 (0.81, 1.80) 1.10 (0.79, 1.50) 1.30 (0.85, 1.64) 1.45 (0.70, 1.78) 0.626
Immunological biomarkers
 WBC count, *109/L 5.40 (4.30, 6.30) 5.21 (4.19, 6.00) 5.32 (4.48, 6.08) 6.30 (4.65, 7.20) 0.187
 hs-CRP, mg/L 0.50 (0.50, 0.50) 0.50 (0.50, 0.50) 0.50 (0.50, 0.50) 0.50 (0.50, 0.58) 0.793
SMA, n (%)
 – 140 (99.29%) 134 (99.26%) 114 (100.00%) 19 (100.00%) 1.000
 ± 1 (0.71%) 1 (0.74%) 0 (0.00%) 0 (0.00%)
AMA, n (%)
 – 141 (100.00%) 134 (33.01%) 114 (100.00%) 19 (100.00%) 0.655
 + 0 (0.00%) 1 (0.74%) 0 (0.00%) 0 (0.00%)
ANA, n (%)
 – 100 (70.92%) 103 (76.30%) 90 (78.95%) 15 (78.95%) 0.515
 ± 33 (23.40%) 22 (16.30%) 15 (13.16%) 3 (15.79%)
 + 8 (5.67%) 10 (7.40%) 9 (7.89%) 1 (5.26%)

Data are described as median and interquartile, and number and percentage.

AFP, alpha-fetoprotein; AMA, anti-mitochondrial antibody; ANA, anti-nuclear antibody; CA125, cancer antigen 125; CA199, cancer antigen 199; CEA, carcinoembryonic antigen; FSH, follicle stimulating hormone; FT3, free triiodothyronine; FT4, free tetraiodothyronine; GH, growth hormone; hs-CRP, hypersensitive C-reaction protein; LH, luteinizing hormone; PRL, prolactin; PSQI, Pittsburgh sleep quality index; SMA, smooth muscle antibody; T3, triiodothyronine; T4, tetraiodothyronine; TSH, thyroid stimulating hormone; TPOAb, thyroid peroxidase antibody; TGAb, thyroglobulin antibody; WBC white blood cell.

*PSQI scores: 0-5 denoting normal sleep quality; 6-10 suggesting a mild sleep disorder; 11-15 indicating a moderate sleep disturbance; 16-20 reflecting a severe sleep disorder; and 21 representing a very severe sleep disorder.